Icyemezo cy’Ikigo cya Amerika gishinzwe imiti n’ibiribwa (FDA) cyemeza ikoreshwa rya Lenacapavir, umuti ushobora gutangwa rimwe mu mezi atandatu mu kurinda ubwandu bushya bwa virusi itera SIDA cyakiriwe n’abafatanyabikorwa batandukanye mu rwego rw’ubuzima nk’intambwe ikomeye mu rugamba rwo guhangana na yo.

Uyu muti wakozwe n’Uruganda rukora imiti muri Amerika, Gilead Sciences, aho umuntu ashobora guterwa urushingiye rumwe mu mezi atandatu bitandukanye no gukoresha ibinini.

Ku wa 18 Kamena Gilead Sciences yatangaje ko urwo rushingiye rwemewe gukoreshwa na FDA.

Ku wa 19 Kamena, Ishami ry’Umuryango w’Abibumbye ryita ku Buzima (WHO) ryatangaje ko kwemerwa na FDA bifungurira inzira icyemezo cyayo kizwi nka prequalification gifasha ibihugu kwemeza no kuba byatumiza iyo miti.

OMS iri gukorana n’Ikigo cy’u Burayi gishinzwe imiti (EMA) binyuze muri gahunda ya Medicines 4 All kugira ngo byorohereze inzego zishinzwe imiti mu bihugu biri gutekereza gukoresha Lenacapavir.

Amabwiriza yerekeye ikoreshwa ry’uwo muti wa Lenacapavir azatangazwa ku wa 14 Nyakanga 2025 mu nama mpuzamahanga ya SIDA izabera i Kigali.

Minisitiri w’Ubuzima mu Rwanda, Dr Sabin Nsanzimana, yavuze ko ubushakashatsi bwerekanye ko urushinge rumwe mu mezi atandatu rutanga uburinzi buhambaye, ariko yongeraho ko “ikiguzi n’imikoranire bigikenewe gusuzumwa.

The FDA just approved lenacapavir, a long-acting injectable HIV prevention medication by @GileadSciences:
• 96 to 100% protection in trials
• One injection every 6 months

But cost & rollout remain barriers

This will be a key topic at #IAS2025 Conference in Kigali,July 2025 https://t.co/7ejLXTczID

— Dr Sabin Nsanzimana (@nsanzimanasabin) June 19, 2025

Lenacapavir ni umwe mu miti y’ubwoko bwa PrEP (Pre-Exposure Prophylaxis) ushobora kwifashishwa mu kurinda abantu bakuru n’ingimbi zifite nibura ibiro 35, ubwandu bwa VIH binyuze mu mibonano mpuzabitsina.

Ibyavuye mu igerageza ryiswe PURPOSE 1 na PURPOSE 2, byagaragaje ko abarenga 99,9% by’abahawe uyu muti batigeze bandura VIH.

Dose ya mbere y’urukingo iterwa umuntu igamije gukangura uturemangingo [B Cells] dushinzwe gukora abasirikare barinda umubiri, mu gihe izindi nkingo zizafasha utwo turemangingo kwiyubakamo ubushobozi bwo kumenya ko agakoko gatera SIDA kinjiye mu mubiri no kugakumira.

OMS yatangaje ko uyu muti mushya wongera amahitamo yo kwirinda HIV, kuko ukoreshwa kabiri gusa mu mwaka, bityo bigafasha abantu benshi batabasha kunywa ibinini buri munsi cyangwa kenshi.

Umuyobozi Mukuru wa Gilead Sciences, Daniel O’Day, yavuze ko kwemererwa gukoreshwa ku muti wabo ari amateka akomeye mu rugamba rwo guhangana na SIDA rumaze imyaka myinshi.

Uru rushinge ruterwa umuntu utarandura. Ntabwo rushobora gukoreshwa ku muntu uzi ko yanduye cyangwa utazi uko ahagaze.

Abahanga bagaragaza ko mbere yo kurukoresha umuntu akwiye kubanza kwisuzumisha kandi hagafatwa ibipimo mu buryo bwizewe kuko utewe urwo rushingiye waranduye bishobora kuba bibi kurushaho.

Ambabwiriza ya OMS ku ikoreshwa ry’urushinge rukumira kwandura SIDA azatangarizwa i Kigali